Skip to main content

Table 2 BO-1051-induced tumor growth delay in GBM-3 xenografts

From: Enhancement of radiosensitivity in human glioblastoma cells by the DNA N-mustard alkylating agent BO-1051 through augmented and sustained DNA damage response

Treatment group

Tumor growth period, days*

Absolute growth delay†

Normalized growth delay‡

Enhancement ratio#

Control

20.2

   

BO-1051

29.5

9.3

  

IR

23.6

3.4

  

BO-1051+IR

36.2

16

6.7

1.97

  1. * Time for subcutaneous tumors to grow from the initial tumor volume to 10 times (see text).
  2. † The number of days for the treated tumors to reach 10 times the initial tumor volume minus the number of days for the control group to reach the same size.
  3. ‡ The number of days for the tumors in the BO-1051+IR group to reach 10 times the initial tumor volume minus the number of days for tumors in the BO-1051-only group to reach the same size.
  4. # Normalized growth delay for the BO-1051+IR group divided by absolute growth delay for the radiation-only group.
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us